Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Antimicrob Agents ; 61(6): 106811, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37037319

RESUMEN

INTRODUCTION: Multidrug-resistant (MDR) Gram-negative organisms cause life-threatening infections, and the incidence is rising globally. Timely therapy for these infections has a direct impact on patient survival. This study aimed to determine the impact of a multidisciplinary diagnostic and antimicrobial stewardship (AMS) workflow on time to appropriate therapy (TAP) for these infections using novel beta-lactam/beta-lactamase inhibitors. METHODS: This was a retrospective quasi-experimental study of adult patients with carbapenem-resistant Enterobacterales (CRE) and multidrug-resistant Pseudomonas (MDR PsA) infections at a 1500 bed university hospital. Included patients who received ≥ 72 hours of ceftazidime-avibactam (CZA) or ceftolozane-tazobactam (C/T) from December 2017 to December 2019. During the pre-intervention period (December 2017 to December 2018), additional susceptibilities (including CZA and C/T) were performed only upon providers' request. In 2019, reflex algorithms were implemented for faster identification and testing of all CRE/MDR PsA isolates. Results were communicated in real-time to the AMS team to tailor therapy. RESULTS: A total of 99 patients were included, with no between-group differences at baseline. The median age was 60 years and 56 (56.7%) were in intensive care at the time of culture collection. Identified organisms included 71 (71.7%) MDR PsA and 26 CRE, of which 18 were carbapenemase producers (Klebsiella-producing carbapenemase = 12, New Delhi metallo-ß-lactamase = 4, Verona integron-encoded metallo-ß-lactamase = 2). The most common infections were pneumonia (49.5%) and bacteraemia (30.3%). A decrease was found in median TAP (103 [IQR 76.0-156.0] vs. 75 [IQR 56-100] hours; P < 0.001). Median time from culture collection to final susceptibility results was shorter in the post-intervention group (123 vs. 93 hours; P < 0.001). CONCLUSION: This study identified improvement in TAP in MDR PsA and CRE infections with implementation of a reflex microbiology workflow and multidisciplinary antimicrobial stewardship initiatives.


Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos , Artritis Psoriásica , Humanos , Persona de Mediana Edad , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Estudios Retrospectivos , Flujo de Trabajo , Artritis Psoriásica/tratamiento farmacológico , Ceftazidima/farmacología , Bacterias Gramnegativas , Inhibidores de beta-Lactamasas/uso terapéutico , Inhibidores de beta-Lactamasas/farmacología , beta-Lactamasas , Carbapenémicos/farmacología , Combinación de Medicamentos , Compuestos de Azabiciclo/farmacología , Pruebas de Sensibilidad Microbiana , Pseudomonas aeruginosa
2.
Transpl Infect Dis ; 20(1)2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29064133

RESUMEN

Infections with carbapenemase-producing carbapenem-resistant Enterobacteriaceae represent an emergent problem worldwide. Treatment of infections caused by New Delhi metallo-beta-lactamase (NDM)-harboring Enterobacteriaceae is particularly challenging as it frequently involves the use of nephrotoxic agents, which is problematic in kidney transplant recipients and non-renal transplant patients with marginal kidney function. We present two cases of urinary tract infections caused by NDM-harboring Enterobacteriaceae successfully treated with a combination of "double carbapenem" and oral fosfomycin.


Asunto(s)
Carbapenémicos/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Enterobacteriaceae/efectos de los fármacos , Fosfomicina/uso terapéutico , Trasplante de Riñón/efectos adversos , Infecciones Urinarias/tratamiento farmacológico , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Carbapenémicos/administración & dosificación , Enterobacteriaceae/enzimología , Infecciones por Enterobacteriaceae/etiología , Infecciones por Enterobacteriaceae/microbiología , Fosfomicina/administración & dosificación , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Resultado del Tratamiento , Infecciones Urinarias/complicaciones , Infecciones Urinarias/microbiología , beta-Lactamasas/biosíntesis , beta-Lactamasas/efectos de los fármacos
3.
Antimicrob Agents Chemother ; 59(10): 5903-8, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26386029

RESUMEN

New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with prolonged hospitalization following an intestinal transplant who developed refractory bacteremia due to a serine carbapenemase-producing pandrug-resistant isolate of Klebsiella pneumoniae. After failing multiple antimicrobial regimens, the patient was successfully treated.


Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Proteínas Bacterianas/biosíntesis , Intestino Delgado/efectos de los fármacos , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , beta-Lactamasas/biosíntesis , Antivirales/uso terapéutico , Compuestos de Azabiciclo/uso terapéutico , Bacteriemia/microbiología , Bacteriemia/patología , Carbapenémicos/uso terapéutico , Ceftazidima/uso terapéutico , Colectomía , Colistina/uso terapéutico , Combinación de Medicamentos , Farmacorresistencia Bacteriana Múltiple , Femenino , Ganciclovir/análogos & derivados , Ganciclovir/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Intestino Delgado/microbiología , Intestino Delgado/trasplante , Infecciones por Klebsiella/microbiología , Infecciones por Klebsiella/patología , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/crecimiento & desarrollo , Meropenem , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Minociclina/análogos & derivados , Minociclina/uso terapéutico , Tienamicinas/uso terapéutico , Tigeciclina , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Valganciclovir
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA